Health Care & Life Sciences » Biotechnology | ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. | Income Statement

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
49.50
343.70
19.90
2.70
9.90
0.50
SG&A Expense
2,318.00
3,257.40
2,044.10
3,441.50
6,037.80
10,188.20
EBIT
2,318.80
2,925.50
2,031.80
3,445.50
6,034.60
10,194.40
Unusual Expense
-
-
110.00
-
-
-
Non Operating Income/Expense
85.50
-
44.90
6.40
21.70
27.40
Interest Expense
-
-
24.00
15.90
7.10
-
Pretax Income
2,230.90
2,925.50
2,121.00
3,455.00
6,020.00
10,167.10
Income Tax
-
70.20
-
-
-
-
Consolidated Net Income
2,230.90
2,855.20
2,121.00
3,455.00
6,020.00
10,167.10
Net Income
2,230.90
2,855.20
2,121.00
3,455.00
6,020.00
10,167.10
Net Income After Extraordinaries
2,230.90
2,855.20
2,121.00
3,455.00
6,020.00
10,167.10
Net Income Available to Common
2,230.90
2,855.20
2,121.00
3,455.00
6,020.00
10,167.10
EPS (Basic)
0.04
0.05
0.02
0.02
0.03
0.04
Basic Shares Outstanding
56,744.70
68,022.80
107,974.10
169,896.40
205,778.30
239,194.90
EPS (Diluted)
0.04
0.04
0.02
0.02
0.03
0.04
Diluted Shares Outstanding
56,744.70
68,022.80
107,974.10
169,896.40
205,778.30
239,194.90
EBITDA
2,268.50
2,913.70
2,024.20
3,438.90
6,027.90
10,187.70
Non-Operating Interest Income
2.30
-
-
-
-
-

About ProMIS Neurosciences

View Profile
Address
1920 Yonge Street
Toronto Ontario M4S 3E2
Canada
Employees -
Website http://www.promisneurosciences.com
Updated 07/08/2019
ProMIS Neurosciences, Inc. operates as a development stage biotech company. It discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and amyotrophic lateral sclerosis. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.